心脏生物标志物可识别社区获得性肺炎患者早期和长期心血管事件风险
该前瞻性研究纳入730例住院社区获得性肺炎患者,随访1年,检测第1天、第4/5天和第30天的心脏生物标志物(proADM、proBNP、proendothelin-1、肌钙蛋白T)和炎症标志物(IL-6、CRP、降钙素原)。92例发生早期(30天内)心血管事件,67例发生长期(1年)事件。校正年龄、既往心脏病、PaO2/FiO2<250 mmHg和脓毒症后,第1天和第30天生物标志物独立预测心血管事件:早期事件OR为proendothelin-1 2.25(95%CI 1.34-3.79)、proADM 2.53(95%CI 1.53-4.20)、proBNP 2.67(95%CI 1.59-4.49)、肌钙蛋白T 2.70(95%CI 1.62-4.49);晚期事件OR为proendothelin-1 3.13(95%CI 1.41-7.80)、proADM 2.29(95%CI 1.01-5.19)、proBNP 2.34(95%CI 1.01-5.56)。第30天IL-6加入proendothelin-1或proADM后OR分别增至3.53和2.80。作者认为心脏生物标志物有助于识别高危患者并优化个体化治疗。
要点
- 住院CAP患者中,92/730例发生30天内心血管事件,67/730例发生1年内心血管事件。
- 第1天和第30天proADM、proBNP、proendothelin-1、肌钙蛋白T独立预测早期事件,OR 2.25-2.70(95%CI均>1)。
- 第1天和第30天proendothelin-1、proADM、proBNP独立预测晚期事件,OR 2.29-3.13(95%CI均>1)。
- 第30天IL-6加入proendothelin-1或proADM后OR分别增至3.53和2.80。
- 发生晚期事件者第4/5天标志物下降后至第30天保持稳定。
适用人群与场景
- 住院的社区获得性肺炎患者,前瞻性随访1年。
研究设计与关键结果
- 前瞻性研究纳入730例住院CAP患者,随访1年;92例发生早期(30天内)心血管事件,67例发生长期(1年)事件。
- 发生心血管事件者初始proADM、proendothelin-1、肌钙蛋白、proBNP和IL-6水平显著更高;发生晚期事件者第4/5天下降后至第30天保持稳定。
- 校正年龄、既往心脏病、PaO2/FiO2<250 mmHg和脓毒症后,第1天和第30天生物标志物独立预测早期事件:proendothelin-1 OR 2.25(95%CI 1.34-3.79)、proADM OR 2.53(95%CI 1.53-4.20)、proBNP OR 2.67(95%CI 1.59-4.49)、肌钙蛋白T OR 2.70(95%CI 1.62-4.49)。
- 晚期事件:proendothelin-1 OR 3.13(95%CI 1.41-7.80)、proADM OR 2.29(95%CI 1.01-5.19)、proBNP OR 2.34(95%CI 1.01-5.56)。
- 第30天IL-6加入proendothelin-1或proADM后OR分别增至3.53和2.80。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为心脏生物标志物有助于识别CAP患者早期和长期心血管事件高风险,可能有助于个体化治疗优化和设计未来干预研究以降低心血管风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Community-acquired pneumonia (CAP) increases the risk of cardiovascular complications during and following the episode. The goal of this study was to determine the usefulness of cardiovascular and inflammatory biomarkers for assessing the risk of early (within 30 days) or long-term (1-year follow-up) cardiovascular events.
METHODS: A total of 730 hospitalized patients with CAP were prospectively followed up during 1 year. Cardiovascular (proadrenomedullin [proADM], pro-B-type natriuretic peptide (proBNP), proendothelin-1, and troponin T) and inflammatory (interleukin 6 [IL-6], C-reactive protein, and procalcitonin) biomarkers were measured on day 1, at day 4/5, and at day 30.
RESULTS: Ninety-two patients developed an early event, and 67 developed a long-term event. Significantly higher initial levels of proADM, proendothelin-1, troponin, proBNP, and IL-6 were recorded in patients who developed cardiovascular events. Despite a decrease at day 4/5, levels remained steady until day 30 in those who developed late events. Biomarkers (days 1 and 30) independently predicted cardiovascular events adjusted for age, previous cardiac disease, Pao2/Fio2 < 250 mm Hg, and sepsis: ORs (95% CIs), proendothelin-1, 2.25 (1.34-3.79); proADM, 2.53 (1.53-4.20); proBNP, 2.67 (1.59-4.49); and troponin T, 2.70 (1.62-4.49) for early events. For late events, the ORs (95% CIs) were: proendothelin-1, 3.13 (1.41-7.80); proADM, 2.29 (1.01-5.19); and proBNP, 2.34 (1.01-5.56). Addition of IL-6 levels at day 30 to proendothelin-1 or proADM increased the ORs to 3.53 and 2.80, respectively.
CONCLUSIONS: Cardiac biomarkers are useful for identifying patients with CAP at high risk for early and long-term cardiovascular events. They may aid personalized treatment optimization and for designing future interventional studies to reduce cardiovascular risk.
参考来源
- Menéndez R, Méndez R, Aldás I, et al. Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers. Chest. 2019. PMID: 31381883. doi:10.1016/j.chest.2019.06.040
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。